Experience from Turkish centers participating in the Early Access Program (EAP): Preliminary real-world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treated advanced melanoma patients

Experience from Turkish centers participating in the Early Access Program (EAP): Preliminary real-world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treated advanced melanoma patients

Objective: We aimed to evaluate the safety of nivolumab + ipilimumab (nivo + ipi) in advanced melanoma patients who had relapsed after ≥1 line of systemic treatment in a real-world setting. Methods: Adult patients with advanced melanoma who had progressed after ≥1 line of systemic treatment were eli...

Full description

Bibliographic Details
Main Authors: Nuri Karadurmus, Mehmet Ali Nahit Sendur, Burcak Karaca, Omer Fatih Olmez, Ilhan Hacibekiroglu, Hasan Senol Coskun, Serkan Degirmencioglu, Yasemin Kemal, Saadettin Kilickap, Ahmet Taner Sumbul, Burc Aydin, Hande Turna, Muhammet Ali Kaplan, Nalan Babacan, Umut Demirci, Alper Ata, Dilek Erdem, Ahmet Ozet, Huseyin Abali
Format: Article
Language:English
Published: Turkiye Klinikleri 2018-12-01
Series:Journal of Oncological Sciences
Online Access:http://www.sciencedirect.com/science/article/pii/S2452336418300542

Internet

http://www.sciencedirect.com/science/article/pii/S2452336418300542

Similar Items